Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226680 | 1.00 | CCR1 (0.45) | CCR1FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL26188298 | 0.93 | CCR1 (0.45) | CCR1CXCR3 | |
| SCHEMBL15096077 | 0.91 | CCR1 (0.37) | CCR1CXCR3 | |
| SCHEMBL15092784 | 0.89 | CCR1 (0.52) | CCR1 | |
| SCHEMBL1846775 | 0.89 | CCR1 (0.55) | CCR1FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL1848601 | 0.89 | CCR1 (0.55) | CCR1FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL3223541 | 0.88 | CCR1 (0.57) | CCR1 | |
| SCHEMBL3232495 | 0.88 | CCR1 (0.57) | CCR1 | |
| SCHEMBL3223629 | 0.88 | CXCR3 (0.39) | CCR1CXCR3EIF2AK3 | |
| SCHEMBL3223618 | 0.88 | CXCR3 (0.39) | CCR1CXCR3EIF2AK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323663-B1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX INC (US) | 2015-02-25 | — | — | EP | claimed |
| US-20100069396-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2010-03-18 | — | — | US | claimed |
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CHEMOCENTRYX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3439653-B1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200289472-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10568870-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CHEMOCENTRYX, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2017-10-12 | — | — | US | disclosed |
| WO-2017176965-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| EP-2323663-B1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2323663-B1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8946240-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946240-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8343975-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. | 2013-01-01 | — | — | US | disclosed |
| US-8343975-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. | 2013-01-01 | — | — | US | disclosed |
| WO-2010030815-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100069396-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069396-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CCR1, CCRL2, CCR3 | CCR1 1/4885FGFR1 128/4885FGFR2 783/4885 |
| US-10568870-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CCR1, CCRL2, CCR3 | CCR1 1/4885FGFR1 128/4885FGFR2 783/4885 |
| US-20200289472-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CCR1, CCRL2, CCR3 | CCR1 1/4885FGFR1 128/4885FGFR2 783/4885 |
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CCR1, CCRL2, CCR3 | CCR1 1/4885FGFR1 128/4885FGFR2 783/4885 |
| US-20100069396-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885FGFR1 2208/4885FGFR2 3356/4885 |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885FGFR1 2208/4885FGFR2 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.